Company Registry

Fairbanks Pharmaceuticals
Profile last edited on: 9/30/2019

Tackling diabetes through beta cell repair and regeneration
Year Founded
First SBIR Year
Latest SBIR Award
Program Status


Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

158 Laurel Street
Concord, MA 01742
   (617) 922-5384
Multiple Locations:   
Congressional District:   03
County:   Middlesex

Public Profile

With a focus on understanding the underlying caused of the disease - ss of insulin from beta cells - not just the symptoms, Fairbanks Pharmaceuticals is developing novel treatments for diabetes. Efforts of the firm organzie around facilitating repair of existing insulin-producing beta cells in the short term and regeneration of new beta cells in the longer term. In October 2018, the firm was awarded the 2018 Boston Innovation Prize by Boehringer Ingelheim which included a golden ticket to LabCentral.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount Project Title
2019 2 NIH $2,023,609
Development of Novel Diabetes Therapies Based on Neutralizing FSTL3 Activity

Key People / Management

  Alan L Schneyer -- Founder, CEO, Chief Scientific Officer

  Elissa Brown -- Director of Strategic Planning Founder

  Alexa Lopez -- Laboratory Technician

  Nolan Meyer -- Laboratory Technician

  Alden Richter -- Laboratory Technician

SBIR firms in the news

There are no news available.